{"id":"W3009751715","doi":"10.1038/s41375-020-0776-2","title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","year":2020,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1510,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Daiichi Sankyo Europe; Scheme for Promotion of Academic and Research Collaboration; Sun Pharma; Servier; Astellas Pharma; Incyte; Italfarmaco; Seagen; Agios Pharmaceuticals; Astex Pharmaceuticals; Celgene; Daiichi-Sankyo; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Gilead Sciences; Ariad Pharmaceuticals; Amgen; Pfizer; Ascentage Pharma","keywords":"Medicine; Dasatinib; Nilotinib; Bosutinib; Discontinuation; Imatinib; Myeloid leukemia; Tyrosine-kinase inhibitor; Internal medicine; Oncology; Intensive care medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001671417,0.001074119,0.001367766,0.003856944,0.0003742301,0.001429713,0.001969991,0.001923948,0.02379],"category_scores_gemma":[0.001979389,0.000296305,0.001548305,0.003634206,0.0003388823,0.001332544,0.001070554,0.001969267,0.01509197],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001496943,"about_ca_system_score_gemma":0.004075973,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002930646,"about_ca_topic_score_gemma":0.004611511,"domain_scores_codex":[0.9991824,0.000216176,0.00015395,0.00005848378,0.0003191217,0.00006995161],"domain_scores_gemma":[0.9992334,0.0002053256,0.0001719151,0.00002152507,0.0002985866,0.00006925183],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008780618,0.00005604856,0.00007576928,0.015665,0.00007158227,0.00007445401,0.00003340776,0.0001760234,0.00038697,0.004435709,0.3031957,0.6757416],"study_design_scores_gemma":[0.00002603925,0.00001884002,0.000162609,0.005677086,0.00004984889,0.0001135439,0.000009826609,0.00001732143,0.00004312519,0.0007505272,0.9931267,0.000004431021],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001813081,0.962051,0.0006075138,0.006545053,0.003228905,0.0002980669,0.001417792,0.0001375383,0.02553282],"genre_scores_gemma":[0.001030803,0.9720477,0.002715148,0.007388079,0.0006667606,0.0002992099,0.002568767,0.00003297607,0.01325053],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.02379,"threshold_uncertainty_score":0.07958549,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04811984751068918,"score_gpt":0.3335786658783663,"score_spread":0.2854588183676771,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}